Entest (ETNI) 10-K 26 Nov 14 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Aug. 31, 2014	Nov. 21, 2014
Document And Entity Information	'	'
Entity Registrant Name	'ENTEST BIOMEDICAL, INC.	'
Entity Central Index Key	'0001449447	'
Document Type	'10-K	'
Document Period End Date	31-Aug-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--08-31	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'No	'
Is Entity's Reporting Status Current?	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Public Float	'	$966,456
Entity Common Stock, Shares Outstanding	'	2,405,570,642
Document Fiscal Period Focus	'FY	'
Document Fiscal Year Focus	'2014	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Aug. 31, 2014	Aug. 31, 2013
Current Assets	'	'
Cash	$734	$9,610
Due from Affiliate	0	34,895
Current Portion of Prepaid Expenses	8,000	8,000
Total Current Assets	8,734	52,505
Property & Equipment (Net of Accumulated Depreciation)	1,919	1,919
Intangible Assets (Net of Accumulated Amortization)	0	270
TOTAL ASSETS	10,653	54,694
Current Liabilities	'	'
Accounts Payable	115,849	101,615
Notes Payable	383,440	272,644
Convertible notes payable, net of discount	'	101,000
Due to Other	8,000	8,000
Accrued Expenses	182,549	258,313
Total Current Liabilities	687,838	741,572
TOTAL LIABILITIES	687,838	741,572
STOCKHOLDERS' EQUITY	'	'
Common Stock, $0.001 par value, authorized 6,000,000,000 shares; issued and outstanding 561,856,768 (par value $0.001) shares and 2,205,570,752 (par value $0.0001) as of August 31, 2013 and 2014 respectively	219,657	561,855
Preferred Stock , $0.001 par value 5,000,000 shares authorized, 0 shares issued and outstanding as of August 31, 2013 and August 31, 2014	'	'
Series AA Preferred Stock, 100,000 shares authorized, 5,000 shares, par vlaue $0.001, issued and outstanding at August 31, 2013 and 100,000 shares (par value $0.0001) as of August 31, 2014	10	5
Series B Preferred Stock, 4,400,000 shares authorized, 3,201,397 (par value $0.001) issued and outstanding as of August 31, 2013 and 4,201,397 (par value $0.0001) issued and outstanding as of August 31, 2014	421	3,201
Series AAA Preferred, 300,000 shares authorized, $0.0001 par value, 0 and 80,000 shares outstanding as of August 31, 2013 and August 31, 2014 respectively	8	0
NonVoting Convertible Preferred, ($1 par value) 200,000 shares authorized, 24,775 and 0 issued and outstanding as of August 31, 2013 and August 31, 2014, respectively	0	24,775
Additional Paid in Capital	5,239,692	3,441,563
Contributed Capital	274,162	274,162
Accumulated Deficit	-6,413,135	-4,992,439
Total Stockholders' Equity	-679,185	-686,878
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY	$10,653	$54,694

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Aug. 31, 2014	Aug. 31, 2013
Statement of Financial Position [Abstract]	'	'
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	6,000,000,000	6,000,000,000
Common stock, shares issued	2,205,570,752	561,856,768
Common stock, shares outstanding	2,205,570,752	561,856,768
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series AA Preferred shares, par value	$0.00	$0.00
Series AA Preferred shares, shares authorized	100,000	100,000
Series AA Preferred shares, shares issued	100,000	5,000
Series AA Preferred shares, shares outstanding	100,000	5,000
Series AAA Preferred shares, par value	$0.00	$0.00
Series AAA Preferred shares, shares authorized	300,000	300,000
Series AAA Preferred shares, shares issued	80,000	0
Series AAA Preferred shares, shares outstanding	80,000	'
Series B Preferred shares, par value	$0.00	$0.00
Series B Preferred shares, shares authorized	4,400,000	4,400,000
Series B Preferred shares, shares issued	4,201,397	3,201,397
Series B Preferred shares, shares outstanding	4,201,397	3,201,397

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended		72 Months Ended
	Aug. 31, 2014	Aug. 31, 2013	Aug. 31, 2014
REVENUES	'	'	'
TOTAL REVENUE	$0	$0	$0
COSTS AND EXPENSES	'	'	'
Research and Development	0	0	145,794
Rent Costs	38,517	37,032	247,477
General and Administrative	265,566	514,310	2,233,043
Incorporation Costs	'	'	408
Consultant's Expenses	76,032	111,655	926,098
Miscellaneous Expenses	'	'	78
Total Costs and Expenses	380,115	662,887	3,552,898
OPERATING LOSS	-380,115	-662,997	-3,552,898
OTHER INCOME AND EXPENSE	'	'	'
Other Income	5,700	70,475	171,223
Gain on issuance of stock at above fair value	6,000	'	6,000
Penalties on Convertible Debentures	'	-63,000	-63,000
Loss on dercognition of assets due to divestiture	'	-22,906	-22,906
Loss on issuance of stock below fair value	-600,994	'	-600,994
Loss on Early Extinguishment of Debt	'	'	-18,647
Income generated from revenue Share Agreement	'	'	187,699
Expenses incurred from Revenue Share Agreement	'	'	-145,362
Loss on impairment of intangible assets	'	'	-683,333
Interest Expense	-27,165	-41,762	-129,806
Interest Expense attributable to amortization of discount	'	-140,307	-537,215
Loss on Impairment of Goodwill	'	-405,000	-405,000
Gain on dercognition of Liabilities due to Divestiture	'	61,168	61,168
Expense attributable to issuance of common shares below par value	-420,369	-56,343	-476,712
Expenses attributable to issuance of shares pursuant to contractual obligation	'	-32,911	-56,779
Expenses attributable to issuance of Non Voting Convertible Preferred Shares in connection with Stock Purchase Agreement	'	'	-75,000
TOTAL OTHER INCOME AND EXPENSE	-1,036,828	-630,586	-2,788,664
LOSS BEFORE INCOME TAXES	-1,416,943	-1,293,583	-6,341,562
Income Taxes	0	0	0
NET LOSS	-1,416,943	-1,293,583	-6,341,562
Beneficial conversion feature attributable to issuance of NonVoting Preferred Stock	'	'	-32,142
NET LOSS from continuing Operations	-1,416,943	-1,293,583	-6,373,704
Net Income (Loss) from discontinued operations	-3,753	-34,554	-39,431
NET LOSS available to common shareholders	($1,420,696)	($1,328,137)	($6,413,135)
BASIC AND DILUTED EARNINGS (LOSS) PER SHARE	($0.00)	($0.00)	'
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	1,470,725,875	458,310,240	'

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders Equity (USD $)	Common Stock	Series AA Preferred Stock	Series AAA Preferred	Series B Preferred	Non Voting Convertible Preferred	Additional Paid-In Capital	Contributed Capital	Accumulated Deficit during the Development Stage	Total
Beginning balance, Amount at Aug. 21, 2008	$0	$0	$0	$0	$0	$0	$0	$0	$0
Beginning balance, Shares at Aug. 21, 2008	0	0	0	0	0	'	'	'	'
Shares issued to parent, Shares	1,500	'	'	'	'	'	'	'	'
Shares issued to parent, Amount	408	'	'	'	'	'	'	'	408
Net Loss for period	'	'	'	'	'	'	'	-408	-408
Ending balance, Amount at Aug. 31, 2008	408	0	0	0	0	0	0	-408	0
Ending balance, Shares at Aug. 31, 2008	1,500	0	0	0	0	'	'	'	'
Recapitalization in connection with reverse acquisition, Shares	9,998,500	'	'	'	'	'	'	'	'
Recapitalization in connection with reverse acquisition, Amount	9,592	'	'	'	'	-9,592	0	'	0
Common Shares issued in Reverse Acquisition, Shares	4,000,000	'	'	'	'	'	'	'	'
Common Shares issued in Reverse Acquisition, Amount	4,000	'	'	'	'	-4,000	0	'	0
Increases in Contributed capital	'	'	'	'	'	'	485	'	485
Common Shares issued for Cash, Shares	1,000,000	'	'	'	'	'	'	'	'
Common Shares issued for Cash, Amount	1,000	'	'	'	'	99,000	0	'	100,000
Restricted Stock Awards issued to employee, Shares	2,000,000	'	'	'	'	'	'	'	'
Restricted Stock Awards issued to employee, Amount	2,000	'	'	'	'	-2,000	0	'	0
Common Shares issued to consultant, Shares	50,000	'	'	'	'	'	'	'	'
Common Shares issued to consultant, Amount	50	'	'	'	'	199,950	0	'	200,000
Restricted Stock Awards to consultant, Amount	'	'	'	'	'	24,725	0	'	24,725
Net Loss for period	'	'	'	'	'	'	'	-245,515	-245,515
Ending balance, Amount at Aug. 31, 2009	17,050	0	0	0	0	308,083	485	-245,923	79,695
Ending balance, Shares at Aug. 31, 2009	17,050,000	0	0	0	0	'	'	'	'
Increases in Contributed capital	'	'	'	'	'	'	14,619	'	14,619
Common Shares issued for Cash, Shares	500,000	'	'	'	'	'	'	'	'
Common Shares issued for Cash, Amount	500	'	'	'	'	49,500	'	'	50,000
Common Stock issued as Compensation, Shares	3,040	'	'	'	'	'	'	'	'
Common Stock issued as Compensation, Amount	3	'	'	'	'	4,557	'	'	4,560
Restricted Stock Awards to consultant, Amount	'	'	'	'	'	175,275	'	'	175,275
Net Loss for period	'	'	'	'	'	'	'	-544,891	-544,891
Ending balance, Amount at Aug. 31, 2010	17,553	0	0	0	0	537,415	15,104	-790,814	-220,742
Ending balance, Shares at Aug. 31, 2010	17,553,040	0	0	0	0	'	'	'	'
Increases in Contributed capital	'	'	'	'	'	'	259,058	'	259,058
Common Shares issued for Cash, Shares	2,217,600	'	'	'	'	'	'	'	'
Common Shares issued for Cash, Amount	2,217	'	'	'	'	215,383	'	'	217,600
Restricted Stock Awards issued to employee, Shares	50,000	'	'	'	'	'	'	'	'
Restricted Stock Awards issued to employee, Amount	50	'	'	'	'	-50	'	'	'
Common Shares issued to consultant, Shares	74,383	'	'	'	'	'	'	'	'
Common Shares issued to consultant, Amount	74	'	'	'	'	121,967	'	'	122,041
Common Stock issued as Compensation, Amount	'	'	'	'	'	303,235	'	'	303,399
Common Stock issued to employees, Shares	163,766	'	'	'	'	'	'	'	'
Common Stock issued to employees, Amount	164	'	'	'	'	'	'	'	'
Common Shares issued for Debt, Shares	781,712	'	'	'	'	'	'	'	'
Common Shares issued for Debt, Amount	780	'	'	'	'	340,387	'	'	341,167
Discount on Convertible Debt recognized	'	'	'	'	'	88,998	'	'	88,998
Preferred Stock issued for Accrued salaries, Shares	'	5,000	'	'	'	'	'	'	'
Preferred Stock issued for Accrued salaries, Amount	'	5	'	'	'	1,995	'	'	2,000
Restricted Stock Awards to consultant, Amount	'	'	'	'	'	10,000	'	'	10,000
Net Loss for period	'	'	'	'	'	'	'	-954,398	-954,398
Discontinued Operations	'	'	'	'	'	'	'	2,615	2,615
Ending balance, Amount at Aug. 31, 2011	20,838	5	0	0	0	1,619,330	274,162	-1,742,597	171,738
Ending balance, Shares at Aug. 31, 2011	20,840,501	5,000	0	0	0	'	'	'	'
Restricted Stock Awards issued to employee, Shares	77,000,000	'	'	'	'	'	'	'	'
Restricted Stock Awards issued to employee, Amount	77,000	'	'	'	'	-77,000	'	'	0
Restricted Stock Awards issued as compensation expense	'	'	'	'	'	58,491	'	'	58,491
Common Shares issued for Debt, Shares	110,635,695	'	'	'	'	'	'	'	'
Common Shares issued for Debt, Amount	110,635	'	'	'	'	258,424	'	'	369,059
Discount on Convertible Debt recognized	'	'	'	'	'	350,915	'	'	350,915
Common Shares issued for services, Shares	3,272,000	'	'	'	'	'	'	'	'
Common Shares issued for services, Amount	3,269	'	'	'	'	168,481	'	'	171,750
Common Shares issued for intangible assets, Shares	2,500,000	'	'	'	'	'	'	'	'
Common Shares issued for intangible assets, Amount	2,500	'	'	'	'	697,500	'	'	700,000
Common Shares issued for interest, Shares	3,060,005	'	'	'	'	'	'	'	'
Common shares issued for interest, Amount	3,060	'	'	'	'	2,840	'	'	5,980
Cancellation of Common Shares Issued, Shares	-90,000	'	'	'	'	'	'	'	'
Cancellation of Common Shares Issued, Amount	-83	'	'	'	'	-86,687	'	'	-86,687
Restricted Stock Awards to consultant, Shares	15,000,000	'	'	'	'	'	'	'	'
Restricted Stock Awards to consultant, Amount	15,000	'	'	'	'	-15,000	'	'	0
Series B Preferred Dividend paid, Shares	'	'	'	3,201,397	'	'	'	'	'
Series B Preferred Dividend paid, Amount	'	'	'	3,201	'	-3,201	'	'	0
Issuance of Non Voting Convertible Preferred Shares	'	'	'	'	75,000	'	'	'	'
Issuance of Non Voting Convertible Preferred Shares, Amount	'	'	'	'	75,000	'	'	'	75,000
Recognition of Beneficial Conversion Feature	'	'	'	'	'	32,142	'	'	32,142
Shares issued pursuant to Contractual Obligations, Shares	6,274,726	'	'	'	'	'	'	'	'
Shares issued pursuant to Contractual Obligations, Amount	6,274	'	'	'	'	17,594	'	'	23,868
Cancellation of Restricted Stock Award to Employee, Shares	-15,000,000	'	'	'	'	'	'	'	'
Cancellation of Restricted Stock Award to Employee, Amount	-15,000	'	'	'	'	6,813	'	'	-8,187
Net Loss for period	'	'	'	'	'	'	'	-1,885,824	-1,885,824
Beneficial Conversion Feature Deemed Dividend	'	'	'	'	'	'	'	-32,142	-32,142
Discontinued Operations	'	'	'	'	'	'	'	-3,739	-3,739
Ending balance, Amount at Aug. 31, 2012	223,493	5	0	3,201	75,000	3,030,642	274,162	-3,664,302	-57,799
Ending balance, Shares at Aug. 31, 2012	223,492,927	5,000	0	3,201,397	75,000	'	'	'	'
Common Shares issued for Cash, Shares	37,640,314	'	'	'	'	'	'	'	'
Common Shares issued for Cash, Amount	37,640	'	'	'	'	26,660	'	'	64,300
Restricted Stock Awards issued as compensation expense	'	'	'	'	'	123,200	'	'	123,200
Common Shares issued for Debt, Shares	172,186,165	'	'	'	'	'	'	'	172,186,165
Common Shares issued for Debt, Amount	172,186	'	'	'	'	2,273	'	'	174,459
Discount on Convertible Debt recognized	'	'	'	'	'	63,000	'	'	63,000
Common Shares issued for interest, Shares	3,035,894	'	'	'	'	'	'	'	'
Common shares issued for interest, Amount	3,036	'	'	'	'	'	'	'	3,036
Issuance of Non Voting Convertible Preferred Shares	51,589,685	'	'	'	-50,225	'	'	'	'
Issuance of Non Voting Convertible Preferred Shares, Amount	51,589	'	'	'	-50,225	5,685	'	'	7,049
Shares issued pursuant to Contractual Obligations, Shares	32,911,783	'	'	'	'	'	'	'	32,911,783
Shares issued pursuant to Contractual Obligations, Amount	32,911	'	'	'	'	'	'	'	32,911
Common shares issued as legal settlement, Shares	41,000,000	'	'	'	'	'	'	'	'
Common shares issued as legal settlement, Amount	41,000	'	'	'	'	155,800	'	'	196,800
Discount on penalty on Convertible Note recognized	'	'	'	'	'	34,303	'	'	34,303
Net Loss for period	'	'	'	'	'	'	'	-1,293,583	-1,293,583
Discontinued Operations	'	'	'	'	'	'	'	-34,554	-34,554
Ending balance, Amount at Aug. 31, 2013	561,855	5	0	3,201	24,775	3,441,563	274,162	-4,992,439	-686,878
Ending balance, Shares at Aug. 31, 2013	561,856,768	5,000	0	3,201,397	24,775	'	'	'	'
Restricted Stock Awards issued as compensation expense	'	'	'	'	'	123,200	'	'	123,200
Common Stock issued as Compensation, Shares	12,500,000	'	'	'	'	'	'	'	'
Common Stock issued as Compensation, Amount	1,250	'	'	'	'	5,000	'	'	6,250
Common Shares issued for Debt, Shares	1,591,888,587	'	'	'	'	'	'	'	'
Common Shares issued for Debt, Amount	655,889	'	'	'	'	607,500	'	'	551,889
Preferred Stock issued for Accrued salaries, Shares	'	95,000	80,000	1,000,000	'	'	'	'	'
Preferred Stock issued for Accrued salaries, Amount	'	95	8	100	'	20,797	'	'	21,000
Issuance of Non Voting Convertible Preferred Shares	39,325,397	'	'	'	-24,775	'	'	'	'
Issuance of Non Voting Convertible Preferred Shares, Amount	39,325	'	'	'	-24,775	'	'	'	14,550
Reduction in par value	-1,038,662	-90	'	-2,880	'	1,041,622	'	'	'
Net Loss for period	'	'	'	'	'	'	'	-1,416,943	-1,416,943
Discontinued Operations	'	'	'	'	'	'	'	-3,753	-3,753
Ending balance, Amount at Aug. 31, 2014	$219,657	$10	$8	$421	$0	$5,239,692	$274,162	($6,413,135)	($679,185)
Ending balance, Shares at Aug. 31, 2014	2,205,570,752	100,000	80,000	4,201,397	0	'	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended		72 Months Ended
	Aug. 31, 2014	Aug. 31, 2013	Aug. 31, 2014
OPERATING ACTIVITIES	'	'	'
Net (loss)	($1,416,943)	($1,293,583)	($6,341,562)
Adjustments to reconcile net loss to net cash used by operating activities:	'	'	'
Depreciation Expense	'	2,073	16,125
Amortization Expense	270	770	2,287
Stock issued as Compensation to Employees	6,250	99,200	667,530
Stock issued as Compensation to Consultants	'	24,000	532,142
Preferred Stock issued for accrued compensation	21,000	'	23,000
Change in operating assets and liabilities:	'	'	'
(Increase) Decrease in Trade Accounts Receivable	'	2,268	'
(Increase) Decrease in Inventory	'	10,298	'
(Increase) Decrease in Employee Receivable	'	4,349	'
Increase (Decrease) in Accounts Payable	14,234	27,040	115,848
(Increase) Decrease in Prepaid Expenses	'	5,000	-8,000
(Increase) Decrease in Due from Affiliate	34,895	4,245	0
(Increase) Decrease in Deposits	'	1,151	'
Increase (Decrease) in amortization of intangibles	'	'	16,667
Increase (Decrease) in Accrued Expenses	-75,764	138,586	182,547
(Increase) Decrease on gain realized on cancellation of stock	'	'	-94,937
Increase (Decrease) in Loss on Impairment of Intangible Assets	'	'	683,333
Net Cash Provided Used in Operating Activities	-1,416,058	-974,603	-4,205,020
INVESTING ACTIVITIES	'	'	'
Purchase/Sale of Equipment	0	0	-22,884
Net cash Provided by (Used in) Investing Activities	0	0	-22,884
FINANCING ACTIVITIES	'	'	'
(Increase) Decrease in Goodwill from acquisition	'	405,000	'
Noncash Loss on derecognition of assets	'	4,840	4,840
Expenses incurred resulting from issuance of stock for less than par	420,369	56,343	476,712
(Increase) Decrease in gain on issuance of stock for more than fair value	-6,000	'	-6,000
Increase (Decrease) in loss on issuance of stock for less than fair value	600,994	'	600,994
Increase (Decrease) in Common stock issued for cash	'	64,300	431,900
(Increase) Decrease in Intangible Assets (net)	'	'	-2,299
Increase (Decrease) in Common stock issued for expenses	4,420	231,411	340,654
Increase (Decrease) in Due to Affiliate	'	'	8,000
Increase (Decrease) in Notes Payable	267,952	116,832	1,478,337
Increase (Decrease) in Contributed Capital	'	'	274,161
Increase (Decrease) in Additional paid in Capital	123,200	97,304	660,770
Net Cash Provided by Financing Activities	1,410,935	976,030	4,268,069
DISCONTINUED OPERATION	'	'	'
Profit(Loss) from discontinued operations	-3,753	-34,554	-39,431
Net Increase in Cash	-8,876	-33,127	734
Cash at Beginning of Period	9,610	42,737	0
Cash at End of Period	734	9,610	734
Supplemental Disclosure of Noncash investing and financing activities:	'	'	'
Stock issued in payment of Debt	258,156	126,500	1,144,882
Stock issued in Acquisition of McDonald Animal Hospital	'	'	210,000
Stock issued pursuant to Titterington Agreement	'	'	$700,000

Organization_and_Description_o

Organization and Description of Business	12 Months Ended
	Aug. 31, 2014
Accounting Policies [Abstract]	'
Organization and Description of Business	'
	NOTE 1.  ORGANIZATION AND DESCRIPTION OF BUSINESS
	The Company was incorporated in the State of Nevada on September 24, 2008 as JB Clothing Corporation.  Until July 10, 2009, the Company’s principal business objective was the offering of active/leisure fashion design clothing.
	On July 10, 2009 the Company abandoned its efforts in the field of active/leisure fashion design clothing when it acquired 100% of the share capital of Entest BioMedical, Inc., a California corporation, (“Entest CA”).
	The Company’s current business consists of the development and commercialization of immunotherapeutic therapies for the veterinary market as well as the acquisition and operation of veterinary hospitals.

Summary_of_Significant_Account

Summary of Significant Accounting Plicies	12 Months Ended
	Aug. 31, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	NOTE 2.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	A. BASIS OF ACCOUNTING
	The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted an August 31 fiscal year-end.   The Company recognizes revenue from services and product sales when the following four revenue recognition criteria are met: persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the selling price is fixed or determinable, and collectability is reasonably assured. Product sales and service revenues are recorded when the products are delivered and title passes to customers. The customer’s credit card is authorized and charged, or checks/cash are received at the time the services are rendered, thereby providing reasonable assurance of collectability.
	B. PRINCIPLES OF CONSOLIDATION
	The consolidated financial statements include the accounts of Entest CA, the Company’s wholly owned subsidiary. Significant inter-company transactions have been eliminated.
	C. USE OF ESTIMATES
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	D. CASH EQUIVALENTS
	The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
	E. PROPERTY AND EQUIPMENT
	As of August 31, 2014 Property and Equipment consists of $1,919 of Computer equipment. No depreciation expense has been recorded with regards to this equipment as it has yet to be put into service
	F. FAIR VALUE OF FINANCIAL INSTRUMENTS
	Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.  A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:
	Level 1:  Quoted prices in active markets for identical assets or liabilities
	Level 2:  Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.
	Level 3:  Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The Company’s financial instruments as of August 31, 2014 consisted of $ 383,440 of Notes Payable and $8,000 due to TheraCyte, Inc.. The fair value of all of the Company’s financial instruments as of August 31, 2014 were valued according to the Level 3 input. The carrying amount of the financial instruments is equal to the fair value as determined by the Company.
	The Company has determined that there are no Level 1 or Level 2 inputs for determining the fair value of the Company’s financial instruments. Fair value was determined by the Company utilizing its own assumptions and estimation. There were no transfers between levels for the period presented.
	G. INCOME TAXES
	The Company accounts for income taxes using the liability method prescribed by ASC 740, “ Income Taxes. ” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.
	The Company applied the provisions of ASC 740-10-50, “Accounting for Uncertainty in Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of August 31, 2014 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.
	The Company generated a deferred tax credit through net operating loss carry forward.  However, a valuation allowance of 100% has been established.
	Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.
	H.  BASIC EARNINGS (LOSS) PER SHARE
	The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. All convertible debt has an anti-dilutive effect on the EPS, therefore Diluted earnings per share are the same as basic earnings per share.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	12 Months Ended
	Aug. 31, 2014
Accounting Changes and Error Corrections [Abstract]	'
Recent Accounting Pronouncements	'
	NOTE 3.  RECENT ACCOUNTING PRONOUNCEMENTS
	The following accounting standards updates were recently issued and have not yet been adopted by us. These standards are currently under review to determine their impact on our consolidated financial position, results of operations, or cash flows.
	On January 31, 2013, the FASB issued Accounting Standards Update [ASU] 2013-01, entitled Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. The guidance in ASU 2013-01 amends the requirements in the FASB Accounting Standards Codification [FASB ASC] Topic 210, entitled Balance Sheet. The ASU 2013-01 amendments to FASB ASC 210 clarify that ordinary trade receivables and receivables in general are not within the scope of ASU 2011-11, entitled Disclosure about Offsetting Assets and Liabilities, where that ASU amended the guidance in FASB ASC 210. As those disclosures now are modified with the ASU 2013-01 amendments, the FASB ASC 210 balance sheet offsetting disclosures now clearly are applicable only where reporting entities are involved with bifurcated embedded derivatives, repurchase agreements, reverse repurchase agreements, and securities borrowing and lending transactions that either are offset using the FASB ASC 210 or 815 requirements, or that are subject to enforceable master netting arrangements or similar agreements. ASU 2013-01 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of this ASU is not expected to have a material impact on our financial statements.
	On February 28, 2013, the FASB issued Accounting Standards Update [ASU] 2013-04, entitled Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date. The ASU 2013-04 amendments add to the guidance in FASB Accounting Standards Codification [FASB ASC] Topic 405, entitled Liabilities and require reporting entities to measure obligations resulting from certain joint and several liability arrangements where the total amount of the obligation is fixed as of the reporting date, as the sum of the following:
	The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors.
	Any additional amounts the reporting entity expects to pay on behalf of its co-obligors.
	While early adoption of the amended guidance is permitted, for public companies, the guidance is required to be implemented in fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments need to be implemented retrospectively to all prior periods presented for obligations resulting from joint and several liability arrangements that exist at the beginning of the year of adoption. The adoption of ASU 2013-04 is not expected to have a material effect on the Company’s operating results or financial position.
	On April 22, 2013, the FASB issued Accounting Standards Update [ASU] 2013-07, entitled Liquidation Basis of Accounting. With ASU 2013-07, the FASB amends the guidance in the FASB Accounting Standards Codification [FASB ASC] Topic 205, entitled Presentation of Financial Statements. The amendments serve to clarify when and how reporting entities should apply the liquidation basis of accounting. The guidance is applicable to all reporting entities, whether they are public or private companies or not-for-profit entities. The guidance also provides principles for the recognition of assets and liabilities and disclosures, as well as related financial statement presentation requirements. The requirements in ASU 2013-07 are effective for annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. Reporting entities are required to apply the requirements in ASU 2013-07 prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of ASU 2013-07 is not expected to have a material effect on the Company’s operating results or financial position.
	Variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies.  Due to the tentative and preliminary nature of those proposed standards, the Company’s management has not determined whether implementation of such standards would be material to its financial statements.

Going_Concern

Going Concern	12 Months Ended
	Aug. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Going Concern	'
	NOTE 4.  GOING CONCERN
	The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $6,413,135 during the period from August 22, 2008 (inception) through August 31, 2014. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
	Management plans to raise additional funds primarily by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise. There is no guarantee that the Company will be able to raise any capital through any type of offerings.

Notes_Payable

Notes Payable	12 Months Ended
	Aug. 31, 2014
Debt Disclosure [Abstract]	'
Notes Payable	'
	NOTE 5.  NOTES PAYABLE
	As of August 31, 2014
	Notes Payable:
	Bio Technology Partners Business Trust	$	58,000
	The Sherman Family Trust (10% Interest)	$	26,700
	The Sherman Family Trust (0% Interest)	$	180,500
	Regen BioPharma Inc. ( See Note 6)	$	10,422
	David Koos ( See Note 6)	$	107,818
	Total	$	383,440
	Convertible Notes Payable
	No Convertible Notes payable outstanding as of August 31, 2014
	As of August 31, 2013
	Notes Payable:
	Bio Technology Partners Business Trust	$	13,550
	The Sherman Family Trust (10% Interest)	$	98,200
	Officer Loans (Note 6)	$	117,588
	Venture Bridge Advisors	$	37,606
	Southridge Partners II LLP	$	5,700
	Total	$	272,644
	Convertible Notes Payable
	8% Convertible Notes Payable, $101,000
	Bio Technology Partners Business Trust has provided a line of credit to the Company in the amount of $200,000 or so much thereof as may be disbursed to, or for the benefit of the Company by Lender in Lender's sole and absolute discretion.   The unpaid principal of this line of credit bears simple interest at the rate of ten percent per annum. Interest is calculated based on the principal balance as may be adjusted from time to time to reflect additional advances or payments made hereunder. Principal balance and accrued interest shall become due and payable in whole or in part at the demand of the Lender. The Sherman Family Trust (10% Interest) has provided a line of credit to the Company in the amount of $700,000 or so much thereof as may be disbursed to, or for the benefit of the Company by Lender in Lender's sole and absolute discretion. The unpaid principal of this line of credit bears simple interest at the rate of ten percent per annum. Interest is calculated based on the principal balance as may be adjusted from time to time to reflect additional advances or payments made hereunder. Principal balance and accrued interest shall become due and payable in whole or in part at the demand of the Lender. $180,500 due to The Sherman Family Trust (0% Interest) is due and payable in whole or in part at the option of the Holder and bears no interest. Amounts due to Regen Biopharma Inc. are due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Aug. 31, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	NOTE 6.  RELATED PARTY TRANSACTIONS
	As of August 31, 2014 the Company remains indebted to David R. Koos in the principal amount of $107,818  due and payable in whole or in part at the demand of David Koos and bearing simple interest at a rate of 15% per annum.
	As of August 31, 2014 the Company remains indebted to Regen Biopharma, Inc. in the principal amount of $10,422  due and payable in whole or in part at the demand of Regen Biopharma, Inc and bearing simple interest at a rate of 10% per annum. David Koos, the Company’s Chairman and CEO, is also the Chairman and CEO of Regen of Regen Biopharma, Inc.
	The Company allows Bio Matrix Scientific Group, Inc, (“BMSN”) and its affiliate, Regen Biopharma, Inc. ( entities under common control with the Company) to share office space with the Company at 4700 Spring Street, Suite 304, La Mesa California, 91941 free of charge.

Income_Taxes

Income Taxes	12 Months Ended
	Aug. 31, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	NOTE 7.  INCOME TAXES
	As of August 31, 2014
	Deferred tax assets:
	Net operating tax carry forwards	$	2,185,106
	Other		-0-
	Gross deferred tax assets		2,185,106
	Valuation allowance		-2,185,106
	Net deferred tax assets	$	-0-
	As of  August 31, 2014  the Company has a Deferred Tax Asset of $ 2,185,106 completely attributable to net operating loss carry forwards of approximately $ 6,426,782  (which expire 20 years from the date the loss was incurred) consisting of:
	(a) $ 13,647 of Net Operating Loss carry forwards acquired in the reverse acquisition of Entest BioMedical, Inc., a California corporation, and
	(b) $ 6,413,135 of Net Operating Loss carry forwards attributable to Entest BioMedical, Inc.
	Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards are expected to be available to reduce taxable income. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized. In addition, the reverse acquisition in which Entest BioMedical, Inc. was involved in 2009 has resulted in a change of control.  Internal Revenue Code Sec 382 limits the amount of income that may be offset by net operating loss (NOL) carryovers after an ownership change. As a result, the Company has recorded a valuation allowance reducing all deferred tax assets to $ -0-.
	Income tax is calculated at the 34% Federal Corporate Rate.

Acquisition_of_Entest_CA

Acquisition of Entest CA	12 Months Ended
	Aug. 31, 2014
Business Combinations [Abstract]	'
Acquisition of Entest CA	'
	NOTE 8.  ACQUISITION OF ENTEST CA
	On July 10, 2009 the Company acquired 100% of Entest CA, a California corporation and wholly owned subsidiary of the Company, from BMSN for consideration consisting of (a) the issuance to BMSN of 10,000,000 newly issued common shares of Entest and (b) the return by Mr. Rick Plote of 10,000,000 shares of Entest’s common stock previously issued to him by Entest for cancellation.

Acquisition_of_the_Assets_of_P

Acquisition of the Assets of Pet Pointers, Inc.	12 Months Ended
	Aug. 31, 2014
Notes to Financial Statements	'
Acquisition of the Assets of Pet Pointers, Inc.	'
	NOTE 9.  ACQUISITION OF THE ASSETS OF PET POINTERS, INC.
	On January 4, 2011 Entest CA acquired from Pet Pointers, Inc., a California corporation doing business as McDonald Animal Hospital (“Seller”), and Dr. Gregory McDonald DVM (“McDonald”) all the goodwill from McDonald and assets of Seller except cash and accounts receivables used in connection with the operation of a veterinary medical clinic located at 225 S. Milpas Street, Santa Barbara, CA 93103 (the "Business").
	Consideration for the acquisition consisted of:
	I. $70,000 in cash
	II. $210,000 of the Company’s common shares valued at the closing price per share as of January 4, 2011
	III. Payment of no more than $78,000 to a creditor of the Seller to be paid in monthly installments of $1,500 per month
	IV. Payment of no more than $25,000 to additional creditors of the Seller to be paid in monthly installments of $825 per month
	V. Payment of $50,000 to McDonald on the first business day of the fourth month following the closing of the acquisition (“Closing”).

Disposition_of_the_Assets_of_P

Disposition of the Assets of Pet Pointers, Inc.	12 Months Ended
	Aug. 31, 2014
Business Combinations [Abstract]	'
Disposition of the Assets of Pet Pointers, Inc.	'
	NOTE 10. DISPOSITION OF THE ASSETS OF PET POINTERS, INC.
	On November 28, 2012 the “Company executed an agreement (“Agreement”) with Gregory McDonald ("McDonald"), Pet Pointers, Inc. ("Pet Pointer") whereby Mc Donald and Pet Pointer would acquire from the Company all assets (with the exception of cash and accounts receivable) utilized by the Company in the operation of the McDonald Animal Hospital, a full service veterinary clinic owned and operated by the Company and located in Santa Barbara, California (“McDonald Asset Sale”).
	On October 10, 2012 a Complaint (“Complaint”) was filed in the Superior Court of the State of California against the Company and David Koos by McDonald, a former employee of the Company, alleging breach of contract and breach of the covenant of good faith and dealing in connection with the assumption of lease obligations by the Company in connection with the acquisition of the assets of Pet Pointers, Inc breach of contract and breach of the covenant of good faith and dealing in connection with an employment agreement enters into with McDonald inc connection with the Acquisition, breach of contract in connection with the Acquisition purchase agreement, breach of the covenant of good faith and dealing in connection with the Acquisition purchase agreement, implied indemnity in connection to amounts owed by McDonald to Anthony and Judi Marinelli, the Internal Revenue Service, and the California Franchise Tax Board, intentional misrepresentation, negligent misrepresentation , failure to pay wages and violations of Sections 2802, 203, and 2806 of the California Labor Code. The Complaint sought judgment for nominal damages, actual damages, compensatory damages, lost wages, compensation, expenses wage benefits and penalties pursuant to California Labor Code Sections 203 et al, 2802 and 2806, indemnification, accrued interest, punitive damages, costs of suit and attorney’s fees.
	As consideration to the Company for the assets acquired, McDonald and Pet Pointers provided to the Company a General release whereby McDonald and Pet Pointer waive, release and discharge the Company and their respective assignees, officers, directors, shareholders, boards, owners, employees, attorneys, agents, trustors, trustees, beneficiaries, heirs, successors, and representatives from all known and unknown claims, demands, causes of action, attorney's fees, costs, or expenses including:
	(1) All claims relating to the Complaint.
	(2) Those owed by McDonald to Anthony and Judi Marinelli which the Company became obligated to pay on McDonald’s behalf pursuant to the asset purchase agreement entered into between the Company and Gregory McDonald and Pet Pointers, Inc on January 4, 2011.
	(3) Those amounts owed by McDonald to the Internal Revenue Service which the Company became obligated to pay on McDonald’s behalf pursuant to the asset purchase agreement entered into between the Company and Gregory McDonald and Pet Pointers, Inc on January 4, 2011.
	(4) Those amounts owed by McDonald to the California Franchise Tax Board which the Company became obligated to pay on McDonald’s behalf pursuant to the asset purchase agreement entered into between the Company and Gregory McDonald and Pet Pointers, Inc on January 4, 2011.
	Assets disposed of pursuant to the Agreement include approximately $4,840 of Property Plant and Equipment net of accumulated depreciation as well as all inventory held at the McDonald Animal Hospital.
	Assets disposed of pursuant to the Agreement also include
	(i) Essentially all intellectual property, including computer software, utilized in connection with the operation of the McDonald Animal Hospital
	(ii) All telephone numbers, fax numbers, service marks, trademarks, trade names, fictitious business names, websites, business email addresses, vendor lists, promotional materials, vendor records and any and all business records including, but not limited to, such items stored in computer memories, microfiche, paper record or by any other means relevant to the operation of the McDonald Animal Hospital.
	(iii) All customer lists, customer contacts, and any and all customer records that are related to the McDonald Animal Hospital.
	As a result of the agreement, the Company recorded a non-cash pre-tax charge for the impairment of goodwill recorded in connection with the acquisition of the McDonald Animal Hospital of approximately $405,000 for the quarter ended November 30, 2012.
	Pursuant to the Agreement, the Company is obligated to make payment of $13,000 within five days of the Closing of the Agreement as such term is defined in the Agreement.
	Pursuant to the Agreement, the Company agrees to waive, release and discharge McDonald and Pet Pointer from all known and unknown claims, demands, causes of action, attorney's fees, costs, or expenses.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Aug. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	NOTE 11. COMMITMENTS AND CONTINGENCIES
	On November 1, 2011, the Company entered into an agreement to lease approximately 2,320 square feet of office space beginning December 1, 2011 for a period of five years.
	Rent to be charged to the Company pursuant to the lease is as follows:
	$2,996 per month for the period beginning December 1, 2011 and ending November 30, 2012
	$3,116 per month for the period beginning December 1, 2012 and ending November 30, 2013
	$3,241 per month for the period beginning December 1, 2013 and ending November 30, 2014
	$3,371 per month for the period beginning December 1, 2014 and ending November 30, 2015
	$3,506 per month for the period beginning December 1, 2015 and ending November 30, 2016
	This property is utilized as office space. The Company believes that the foregoing property is adequate to meet its current needs. While it is anticipated that the Company will require access to laboratory facilities in the future, the Company believes that access to such facilities are available from a variety of sources.
	On May 24, 2012, a Complaint (“Complaint”) was filed in the U.S. Bankruptcy Court for the District of Oregon against the Company by Titterington Veterinary Services Inc. (“TVS”). The Complaint is an adversary proceeding filed by TVS arising from TVS’s bankruptcy case currently pending in U.S. Bankruptcy Court for the District of Oregon. The Complaint alleges Breach of Contract resulting from the Company’s alleged failure to pay certain expenses the Company was required to pay pursuant to an agreement with TVS, Dr. Ronald Titterington, DVM and Dr. Kathy Snell, DVM (“TVS Agreement”). TVS is seeking a judgment and money award against the Company in an amount to be proven at trial which TVS estimates in the Complaint to be up to $50,000. TVS is also seeking a judgment and order against the Company to provide an accounting of all revenues received by the Company pursuant to the TVS Agreement, all expenses paid, unpaid, and due and owing  pursuant to the TVS Agreement as well as a revenue share which TVS claims is due them pursuant to the TVS Agreement. TVS is also seeking a judgment requiring the Company to turn over a sum of money equal to expenses the Company was obligated to pay pursuant to the TVS Agreement. TVS is also seeking attorney’s fees and expenses.  The Company believes that the allegations in the complaint are without merit and intends to vigorously defend its interests in this matter. At this time, it is not possible to predict the ultimate outcome of these matters and an outcome unfavorable to the Company may have a material adverse effect on the Company. On September 19, 2012 the Plaintiff’s Claim for Relief for turnover and an accounting under 11 U.S.C. § 542 and the Plaintiff's Claim for Relief for attorney fees were dismissed with prejudice and , as per the claim of breach of contract, the proceeding was transferred to the United States Bankruptcy Court for the District of Southern California for all further proceedings. This Complaint was dismissed in its entirety on June 30, 2014.
	There were no other legal proceedings against the Company with respect to matters arising in the ordinary course of business. The Company is not involved in any other litigation either as plaintiffs or defendants, and has no knowledge of any threatened or pending litigation against the Company.

Stockholders_Equity

Stockholders Equity	12 Months Ended
	Aug. 31, 2014
Equity [Abstract]	'
Stockholders Equity	'
	NOTE 12. STOCKHOLDERS EQUITY
	The stockholders' equity section of the Company contains the following classes of capital stock as of August 31, 2014:
	Common Stock:
	$0.0001 par value, 6,000,000,000 shares authorized and 2,205,570,752 shares issued and outstanding as of August 31, 2014.
	Preferred Stock:
	$0.0001 par value 5,000,000 shares authorized of which
		(a)	100,000 are authorized as Series AA Preferred Stock of which 100,000 shares are issued and outstanding  as of  August 31, 2014  and
		(b)	4,400,000 are authorized as Series B Preferred Stock of which 4,201,397 shares are issued and outstanding as of August31, 2014.
	(c) 300,000  are authorized as Series AAA Preferred Stock of which 80,000 shares are issued and outstanding  as of  August 31, 2014
	Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a “Liquidation”), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series B Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.10 per share of Series B Preferred Stock (the “Liquidation Amount”) plus all declared and unpaid dividends thereon, for each share of Series B Preferred Stock held by them.
	If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series B Preferred Stock, then the entire net assets of the Company shall be distributed among the holders of the Series B Preferred Stock, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions may be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board..
	Non Voting Convertible Preferred Stock having a $1.00 par value:
	200,000 shares authorized of which 0 shares are issued and outstanding as of August 31, 2014 .
	Non Voting Convertible Preferred Stock shall convert at the option of the holder into shares of the corporation’s common stock at a conversion price equal to seventy percent (70%) of the lowest Closing Price for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s intent to convert.
	“CLOSING PRICE" shall mean the closing bid price for the corporation’s common stock on the Principal Market on a Trading Day as reported by Bloomberg Finance L.P.
	“PRINCIPAL MARKET" shall mean the principal trading exchange or market for the corporation’s common stock.
	“TRADING DAY” shall mean a day on which the Principal Market shall be open for business.

Stock_Transactions

Stock Transactions	12 Months Ended
	Aug. 31, 2014
Accounting Policies [Abstract]	'
Stock Transactions	'
	NOTE 13. STOCK TRANSACTIONS
	During the quarter ended November 30, 2013:
	On September 4, 2013 The Company issued 27,887,324 of its common shares in satisfaction of $19,800 of convertible notes payable.
	On September 16, 2013 The Company issued 28,000,000 of its common shares in satisfaction of $12,600 of convertible notes payable.
	On September 20, 2013 The Company issued 20,820,513 of its common shares in satisfaction of $5,600 of convertible notes payable and $2,520 of accrued interest on convertible notes payable.
	On September 23, 2013 The Company issued 39,325,397 of its common shares in conversion of 24,775 of the Company’s Non Voting Convertible Preferred Stock
	On September 24, 2013 The Company issued 27,9487,18 of its common shares in satisfaction of $10,900 of convertible notes payable.
	On September 27, 2013 The Company issued 27,9487,18 of its common shares in satisfaction of $10,900 of convertible notes payable.
	On September 30, 2013 The Company issued 60,000,000 of its common shares in satisfaction of $13,550 of notes payable.
	On October 2, 2013 The Company issued 24,848,485 of its common shares in satisfaction of $8,200 of convertible notes payable.
	On October 8, 2013 The Company issued 27,727,273 of its common shares in satisfaction of $6,100 of convertible notes payable.
	On October 9, 2013 The Company issued 28,000,000 of its common shares in satisfaction of $5,600 of convertible notes payable.
	On October 10, 2013 The Company issued 27,777,778 of its common shares in satisfaction of $5,000 of convertible notes payable.
	On October 14, 2013 The Company issued 60,000,000 of its common shares in satisfaction of $13,550 of notes payable.
	On October 15, 2013 The Company issued 27,777,778 of its common shares in satisfaction of $5,000 of convertible notes payable.
	On October 18, 2013 The Company issued 20,652,000 of its common shares in satisfaction of $3,300 of convertible notes payable.
	On October 22, 2013 The Company issued 55,000,000 of its common shares in satisfaction of $6,600 of convertible notes payable.
	On October 24, 2013 The Company issued 27,500,000 of its common shares in satisfaction of $1,400 of convertible notes payable and $1,900 of accrued interest on convertible notes payable.
	On November 23, 2013 The Company issued 60,000,000 of its common shares in satisfaction of $13,550 of notes payable.
	During the quarter ended February 28, 2014:
	On January 20, 2014 the Company issued to David Koos, the Company’s Chairman and CEO, 95,000 shares of the Company’s Series AA Preferred Stock in satisfaction of $10,000 of salary accrued but unpaid owed to David Koos.
	On January 24, 2014 the Company issued to David Koos, the Company’s Chairman and CEO, 1,000,000 shares of the Company’s Series B Preferred Stock in satisfaction of $1,000 of salary accrued but unpaid owed to David Koos.
	On January 24, 2014 the Company issued to David Koos, the Company’s Chairman and CEO, 15,000,000 shares of the Company’s Common Stock in satisfaction of $15,000 of principal indebtedness owed to David Koos.
	On January 28, 2014 the Company issued 115,000,000 shares of the Company’s Common Stock in satisfaction of $10,506 of principal indebtedness.
	During the quarter ended May 31, 2014:
	On March 3, 2014 the Company issued 125,000,000 shares of the Company’s Common Stock in satisfaction of $12,500 of principal indebtedness.
	On March 13, 2014 the Company issued 140,000,000 shares of the Company’s Common Stock in satisfaction of $14,000 of principal indebtedness.
	On March 28, 2014 the Company issued 155,000,000 shares of the Company’s Common Stock in satisfaction of $15,500 of principal indebtedness
	On April 22, 2014 the Company issued 170,000,000 shares of the Company’s Common Stock in satisfaction of $17,000 of principal indebtedness
	On May 16, 2014 the Company issued 125,000,000 shares of the Company’s Common Stock in satisfaction of $12,500 of principal indebtedness.
	On May 22, 2014 the Company issued 80,000 shares of Series AAA Preferred Stock to David R. Koos, the Company’s Chairman, President and CEO as consideration for $10,000 of salary accrued and unpaid owed to David R. Koos by the Company.
	During the quarter ended August 31, 2014:
	On August 7, 2014 the Company issued 195,000,000 shares of the Company’s Common Stock in satisfaction of $19,500 of principal indebtedness.
	On August 11, 2014 the Company issued 12,500,000 shares of the Company’s Common Stock as compensation to an employee.

Subsequent_Events

Subsequent Events	12 Months Ended
	Aug. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	NOTE 14. SUBSEQUENT EVENTS
	On October 22, 2014 the Company issued 200,000,000 shares of the Company’s Common Stock in satisfaction of $20,000 of principal indebtedness.

Summary_of_Significant_Account1

Summary of Significant Accounting Plicies (Policies)	12 Months Ended
	Aug. 31, 2014
Accounting Policies [Abstract]	'
Basis of Accounting	'
	A. BASIS OF ACCOUNTING
	The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted an August 31 fiscal year-end.   The Company recognizes revenue from services and product sales when the following four revenue recognition criteria are met: persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the selling price is fixed or determinable, and collectability is reasonably assured. Product sales and service revenues are recorded when the products are delivered and title passes to customers. The customer’s credit card is authorized and charged, or checks/cash are received at the time the services are rendered, thereby providing reasonable assurance of collectability.
B. PRINCIPLES OF CONSOLIDATION	'
	B. PRINCIPLES OF CONSOLIDATION
	The consolidated financial statements include the accounts of Entest CA, the Company’s wholly owned subsidiary. Significant inter-company transactions have been eliminated.
C. USE OF ESTIMATES	'
	C. USE OF ESTIMATES
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
D. CASH EQUIVALENTS	'
	D. CASH EQUIVALENTS
	The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
E. PROPERTY AND EQUIPMENT	'
	E. PROPERTY AND EQUIPMENT
	As of August 31, 2014 Property and Equipment consists of $1,919 of Computer equipment. No depreciation expense has been recorded with regards to this equipment as it has yet to be put into service
F. FAIR VALUE OF FINANCIAL INSTRUMENTS	'
	F. FAIR VALUE OF FINANCIAL INSTRUMENTS
	Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.  A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:
	Level 1:  Quoted prices in active markets for identical assets or liabilities
	Level 2:  Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.
	Level 3:  Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The Company’s financial instruments as of August 31, 2014 consisted of $ 383,440 of Notes Payable and $8,000 due to TheraCyte, Inc.. The fair value of all of the Company’s financial instruments as of August 31, 2014 were valued according to the Level 3 input. The carrying amount of the financial instruments is equal to the fair value as determined by the Company.
	The Company has determined that there are no Level 1 or Level 2 inputs for determining the fair value of the Company’s financial instruments. Fair value was determined by the Company utilizing its own assumptions and estimation. There were no transfers between levels for the period presented.
G. INCOME TAXES	'
	G. INCOME TAXES
	The Company accounts for income taxes using the liability method prescribed by ASC 740, “ Income Taxes. ” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.
	The Company applied the provisions of ASC 740-10-50, “Accounting for Uncertainty in Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of August 31, 2014 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.
	The Company generated a deferred tax credit through net operating loss carry forward.  However, a valuation allowance of 100% has been established.
	Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.
H. BASIC EARNINGS (LOSS) PER SHARE	'
	H.  BASIC EARNINGS (LOSS) PER SHARE
	The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. All convertible debt has an anti-dilutive effect on the EPS, therefore Diluted earnings per share are the same as basic earnings per share.

Notes_Payable_Tables

Notes Payable (Tables)	12 Months Ended
	Aug. 31, 2014
Debt Disclosure [Abstract]	'
Notes Payable	'
	Bio Technology Partners Business Trust	$	58,000
	The Sherman Family Trust (10% Interest)	$	26,700
	The Sherman Family Trust (0% Interest)	$	180,500
	Regen BioPharma Inc. ( See Note 6)	$	10,422
	David Koos ( See Note 6)	$	107,818
	Total	$	383,440
	Convertible Notes Payable
	No Convertible Notes payable outstanding as of August 31, 2014
	As of August 31, 2013
	Notes Payable:
	Bio Technology Partners Business Trust	$	13,550
	The Sherman Family Trust (10% Interest)	$	98,200
	Officer Loans (Note 6)	$	117,588
	Venture Bridge Advisors	$	37,606
	Southridge Partners II LLP	$	5,700
	Total	$	272,644

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Aug. 31, 2014
Income Tax Disclosure [Abstract]	'
Deferred tax assets	'
	As of August 31, 2014
	Deferred tax assets:
	Net operating tax carry forwards	$	2,185,106
	Other		-0-
	Gross deferred tax assets		2,185,106
	Valuation allowance		-2,185,106
	Net deferred tax assets	$	-0-

Organization_and_Description_o1

Organization and Description of Business (Details Narrative)	Jul. 10, 2009
Accounting Policies [Abstract]	'
Acquisition of share capital of Entest BioMedical, Inc. (bEntest CA")	100.00%

Summary_of_Significant_Account2

Summary of Significant Accounting Plicies (Details Narrative) (USD $)	Aug. 31, 2014
Accounting Policies [Abstract]	'
Computer equipment	$1,919
Notes payable	383,440
Due to TheraCyte, Inc	$8,000

Going_Concern_Details_Narrativ

Going Concern (Details Narrative) (USD $)	12 Months Ended		72 Months Ended
	Aug. 31, 2014	Aug. 31, 2013	Aug. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'	'	'
Net losses	($1,420,696)	($1,328,137)	($6,413,135)

Notes_Payable_Notes_Payable_De

Notes Payable - Notes Payable (Details) (USD $)	Aug. 31, 2014	Aug. 31, 2013
Debt Disclosure [Abstract]	'	'
Bio Technology Partners Business Trust	$58,000	$13,550
The Sherman Family Trust (10% Interest)	26,700	98,200
The Sherman Family Trust (0% Interest)	180,500	'
Officer Loans (Note 6)	'	117,588
Regen BioPharma Inc. ( See Note 6)	10,422	'
David Koos ( See Note 6)	107,818	'
Venture Bridge Advisors	'	37,606
Southridge Partners II LLP	'	5,700
Total	$383,440	$272,644

Notes_Payable_Details_Narrativ

Notes Payable (Details Narrative) (USD $)	Aug. 31, 2014
Debt Disclosure [Abstract]	'
Lines of credit provided by Bio Technology Partners Business Trust and Venture Bridge Advisors, each	$200,000
Unpaid principal lines of credit, simple interest rate per annum	10.00%
Line of credit provided by Sherman Family Trust (10% interest)	700,000
Loaned to the Company by Southridge Partners II LLP	$5,700

Related_Party_Transactions_Det

Related Party Transactions (Details Narrative) (USD $)	Aug. 31, 2014	Aug. 31, 2013
Related Party Transactions [Abstract]	'	'
Amount due to CEO	$107,818	'
Amount due to CEO, interest rate	15.00%	'
Amount due to Regen BioPharma, Inc.	$10,422	'
Amount due to Regen BioPharma, Inc., interest rate	10.00%	'

Income_Taxes_Deferred_tax_asse

Income Taxes - Deferred tax assets (Details) (USD $)	Aug. 31, 2014
Income Tax Disclosure [Abstract]	'
Net operating tax carry forwards	$2,185,106
Other	0
Gross deferred tax assets	2,185,106
Valuation allowance	-2,185,106
Net deferred tax assets	$0

Income_Taxes_Details_Narrative

Income Taxes (Details Narrative) (USD $)	12 Months Ended
	Aug. 31, 2014
Income Tax Disclosure [Abstract]	'
Deferred tax asset	$2,185,106
Net operating loss carry forwards	6,426,782
Net operating loss carry forwards acquired in the reverse acquisition of Entest BioMedical, Inc.	13,647
Net operating loss carry forwards attributable to Entest BioMedical, Inc.	6,413,135
Deferred tax assets, net valuation allowance	$0
Federal Corporate Rate income tax	34.00%

Acquisition_of_Entest_CA_Detai

Acquisition of Entest CA (Details Narrative)	Jul. 10, 2009
Business Combinations [Abstract]	'
Acquisition of Entest CA	100.00%
Newly issued common shares of Entest	10,000,000
Cancellation of shares of common stock	10,000,000

Acquisition_of_the_Assets_of_P1

Acquisition of the Assets of Pet Pointers, Inc. (Details Narrative) (USD $)	44 Months Ended
	Aug. 31, 2014	Jan. 04, 2011
Notes to Financial Statements	'	'
Acquisition of cash	$70,000	'
Acquisition of common shares	'	210,000
Maximum payment to creditor	78,000	'
Monthly installments to creditor	1,500	'
Maximum payment to additional creditors	25,000	'
Monthly installments to additional creditors	825	'
Monthly payment to McDonald	$50,000	'

Disposition_of_the_Assets_of_P1

Disposition of the Assets of Pet Pointers, Inc. (Details Narrative) (USD $)	2 Months Ended	3 Months Ended
	Nov. 28, 2012	Nov. 30, 2012
Business Combinations [Abstract]	'	'
Asset disposal, property plant and equipment	$4,840	'
Impairment of goodwill	'	405,000
Obligated payment, Closing of agreement	'	$13,000

Commitments_and_Contingencies_

Commitments and Contingencies (Details Narrative) (USD $)	12 Months Ended
	Nov. 30, 2016	Nov. 30, 2015	Nov. 30, 2014	Nov. 30, 2013	Nov. 30, 2012	24-May-12
Commitments and Contingencies Disclosure [Abstract]	'	'	'	'	'	'
Office monthly lease payments	$3,506	$3,371	$3,241	$3,116	$2,996	'
Titterington Veterinary Services money award sought	'	'	'	'	'	$50,000

Stockholders_Equity_Details_Na

Stockholders Equity (Details Narrative) (USD $)	Aug. 31, 2014	22-May-14	Jan. 24, 2014	Jan. 20, 2014	Aug. 31, 2013
Equity [Abstract]	'	'	'	'	'
Common stock, par value	$0.00	'	'	'	$0.00
Common stock, shares authorized	6,000,000,000	'	'	'	6,000,000,000
Common stock, shares issued	2,205,570,752	'	'	'	561,856,768
Common stock, shares outstanding	2,205,570,752	'	'	'	561,856,768
Preferred stock, par value	$0.00	'	'	'	$0.00
Preferred stock, shares authorized	5,000,000	'	'	'	5,000,000
Series AA Preferred shares, shares authorized	100,000	'	'	'	100,000
Series AA Preferred shares, par value	$0.00	'	'	'	$0.00
Series AA Preferred shares, shares issued	100,000	'	'	95,000	5,000
Series AA Preferred shares, shares outstanding	100,000	'	'	'	5,000
Series B Preferred shares, shares authorized	4,400,000	'	'	'	4,400,000
Series B Preferred shares, shares issued	4,201,397	'	1,000,000	'	3,201,397
Series AAA Preferred shares, shares authorized	300,000	'	'	'	300,000
Series AAA Preferred shares, shares issued	80,000	80,000	'	'	0
Series AAA Preferred shares, shares outstanding	80,000	'	'	'	'
NonVoting Convertible Preferred shares, par value	$1	'	'	'	'
NonVoting Convertible Preferred shares, shares authorized	200,000	'	'	'	'
NonVoting Convertible Preferred shares, shares issued and outstanding	0	'	'	'	'
Non Voting Convertible Preferred Stock conversion price percentage	70.00%	'	'	'	'

Stock_Transactions_Details_Nar

Stock Transactions (Details Narrative) (USD $)

Aug. 31, 2014

Aug. 22, 2014

Aug. 11, 2014

Aug. 07, 2014

22-May-14

16-May-14

Apr. 22, 2014

Mar. 28, 2014

Mar. 13, 2014

Mar. 03, 2014

Jan. 28, 2014

Jan. 24, 2014

Jan. 20, 2014

Nov. 23, 2013

Oct. 24, 2013

Oct. 22, 2013

Oct. 18, 2013

Oct. 15, 2013

Oct. 14, 2013

Oct. 10, 2013

Oct. 09, 2013

Oct. 08, 2013

Oct. 02, 2013

Sep. 30, 2013

Sep. 27, 2013

Sep. 24, 2013

Sep. 23, 2013

Sep. 20, 2013

Sep. 16, 2013

Sep. 04, 2013

Aug. 31, 2013

Accounting Policies [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common shares issued in satisfaction of convertible notes payable

'

200,000,000

'

195,000,000

'

125,000,000

170,000,000

155,000,000

140,000,000

125,000,000

115,000,000

'

'

60,000,000

27,500,000

55,000,000

20,652,000

27,777,778

60,000,000

27,777,778

28,000,000

27,727,273

24,848,485

60,000,000

27,948,718

27,948,718

'

20,820,513

28,000,000

27,887,324

'

Common shares issued to CEO

'

'

'

'

'

'

'

'

'

'

'

15,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of convertible notes payable satisfied

'

$20,000

'

$19,500

'

$12,500

$17,000

$15,500

$14,000

$12,500

$10,506

$15,000

'

$13,550

$1,400

$6,600

$3,300

$5,000

$13,550

$5,000

$5,600

$6,100

$8,200

$13,550

$10,900

$10,900

'

$5,600

$12,600

$19,800

'

Amount of accrued interest satisfied

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,900

'

'

'

'

'

'

'

'

'

'

'

'

2,520

'

'

'

Common shares issued upon conversion of Non Voting Preferred Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

39,325,397

'

'

'

'

Amount of Non Voting Preferred Stock converted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

24,775

'

'

'

'

Series AA Preferred Stock issued in satisfaction of accrued salary

100,000

'

'

'

'

'

'

'

'

'

'

'

95,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000

Amount of accrued salary satisfied

'

'

'

'

10,000

'

'

'

'

'

'

1,000

10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Series B Preferred Stock issued in satisfaction of accrued salary

4,201,397

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,201,397

Series AAA Preferred Stock issued in satisfaction of accrued salary

80,000

'

'

'

80,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

Common stock issued as employee compensation

'

'

$12,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Subsequent_Events_Details_Narr

Subsequent Events (Details Narrative) (USD $)	Aug. 22, 2014	Aug. 07, 2014	16-May-14	Apr. 22, 2014	Mar. 28, 2014	Mar. 13, 2014	Mar. 03, 2014	Jan. 28, 2014	Jan. 24, 2014	Nov. 23, 2013	Oct. 24, 2013	Oct. 22, 2013	Oct. 18, 2013	Oct. 15, 2013	Oct. 14, 2013	Oct. 10, 2013	Oct. 09, 2013	Oct. 08, 2013	Oct. 02, 2013	Sep. 30, 2013	Sep. 27, 2013	Sep. 24, 2013	Sep. 20, 2013	Sep. 16, 2013	Sep. 04, 2013
Subsequent Events [Abstract]	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'
Common shares issued in satisfaction of convertible notes payable	200,000,000	195,000,000	125,000,000	170,000,000	155,000,000	140,000,000	125,000,000	115,000,000	'	60,000,000	27,500,000	55,000,000	20,652,000	27,777,778	60,000,000	27,777,778	28,000,000	27,727,273	24,848,485	60,000,000	27,948,718	27,948,718	20,820,513	28,000,000	27,887,324
Amount of convertible notes payable satisfied	$20,000	$19,500	$12,500	$17,000	$15,500	$14,000	$12,500	$10,506	$15,000	$13,550	$1,400	$6,600	$3,300	$5,000	$13,550	$5,000	$5,600	$6,100	$8,200	$13,550	$10,900	$10,900	$5,600	$12,600	$19,800